These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31401142)

  • 1. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gorelik Y; Freilich S; Gerassy-Vainberg S; Pressman S; Friss C; Blatt A; Focht G; Weisband YL; Greenfeld S; Kariv R; Lederman N; Dotan I; Geva-Zatorsky N; Shen-Orr SS; Kashi Y; Chowers Y;
    Gut; 2022 Feb; 71(2):287-295. PubMed ID: 34344783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing effects of anti-infliximab antibodies on synergistically-stimulated human coronary artery endothelial cells.
    Ogrič M; Poljšak KM; Lakota K; Žigon P; Praprotnik S; Semrl SS; Čučnik S
    Atherosclerosis; 2019 Dec; 291():1-8. PubMed ID: 31629987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.
    Wojtal KA; Rogler G; Scharl M; Biedermann L; Frei P; Fried M; Weber A; Eloranta JJ; Kullak-Ublick GA; Vavricka SR
    PLoS One; 2012; 7(8):e43361. PubMed ID: 22937039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
    Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
    Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism.
    Bloemendaal FM; Koelink PJ; van Schie KA; Rispens T; Peters CP; Buskens CJ; van der Bilt JD; Bemelman WA; Korf H; Sabino JG; Ponsioen CY; Te Velde AA; D'Haens GRAM; Vermeire S; van den Brink GR; Wildenberg ME
    J Crohns Colitis; 2018 Aug; 12(9):1122-1130. PubMed ID: 29860435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of SHIP, Which Prevents Expression of Interleukin 1β, Is Reduced in Patients With Crohn's Disease.
    Ngoh EN; Weisser SB; Lo Y; Kozicky LK; Jen R; Brugger HK; Menzies SC; McLarren KW; Nackiewicz D; van Rooijen N; Jacobson K; Ehses JA; Turvey SE; Sly LM
    Gastroenterology; 2016 Feb; 150(2):465-76. PubMed ID: 26481854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
    Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
    World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
    Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
    World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
    Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.
    Arnoult C; Brachet G; Cadena Castaneda D; Azzopardi N; Passot C; Desvignes C; Paintaud G; Heuzé-Vourc'h N; Watier H; Gouilleux-Gruart V
    J Immunol; 2017 Jul; 199(2):418-424. PubMed ID: 28584008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-infliximab antibodies: How to compare old and new data?
    Imbrechts M; Van Stappen T; Compernolle G; Tops S; Gils A
    J Pharm Biomed Anal; 2020 Jan; 177():112842. PubMed ID: 31526960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.